ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1385	National Cancer Institute	Html	en	Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing ovarian, fallopian tube, and primary peritoneal cancers and about research aimed at the prevention of them.	oral contraceptives 0.660699 untreated subfertile women 0.554695 population-based case-control study 0.569591 multiple case-control studies 0.577558 tubal ligation 0.612813 ovarian cancer subtypes 0.638647 endometrioid carcinomas 0.557685 Ovarian Cancer Association 0.647707 invasive ovarian tumors 0.625952 tubal intraepithelial carcinoma 0.613375 case-control studies 0.724549 modest increased risk 0.571056 ovarian cancer 0.933826 clear cell carcinomas 0.577194 oral contraceptive therapy 0.556361 ovarian carcinoma 0.65109 ovarian reserve 0.599754 ovarian borderline tumor 0.646023 low-grade ovarian carcinomas. 0.649208 ovarian primary tumors. 0.639278 high-grade carcinomas 0.568553 cohort studies 0.697042 hospital-based case-control studies 0.582441 ovarian cancer cases 0.640486	epithelial ovarian cancers 0.62928 women 0.680224 borderline ovarian tumors 0.627194 prospective cohort studies 0.573074 risk reduction 0.631051 cohort study 0.558817 ovarian carcinomas 0.707015 clear cell cancer 0.56063 ovarian cancers 0.642329 unexposed infertile women 0.555673 observed risk reduction 0.618238 ovarian hyperstimulation 0.617463 significant increased risk 0.567639 high-grade serous carcinomas 0.73533 fallopian tube 0.554218 epithelial ovarian cancer 0.644523 ovarian cancer risk 0.740549 epidemiological studies 0.565 population-based case-control studies 0.621559 gastrointestinal primary tumors 0.557125 Netherlands cohort study 0.55691 ovarian carcinoma subtypes 0.642907 meta-analysis 0.563338 systematic review 0.583056	CLICK HERE
1562	National Cancer Institute	Html	en	Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of hypopharyngeal cancer.	cancer treatment 0.321266 high-dose radiation therapy 0.323579 centimeters 0.269921 cancer spreads 0.270417 malignant tumor cells 0.281954 body 0.305644 chemotherapy 0.290118 PDQ cancer information 0.346817 stage III hypopharyngeal 0.274417 clinical trial search 0.347149 clinical trials 0.698171 hypopharynx 0.280224 cancer information summary 0.319294 metastatic hypopharyngeal cancer 0.310093 clinical trial 0.551798 Recurrent hypopharyngeal cancer 0.306668 patients 0.317052 stage IV hypopharyngeal 0.274937 nearby soft tissue 0.271159 treatment clinical trial 0.275593 NCI PDQ cancer 0.283768 radiation therapy 0.705932 Treatment Editorial Board 0.281401 General information 0.289657 hypopharyngeal cancer 0.722179	general cancer information 0.275426 treatment 0.442202 new cancer treatments 0.272872 NCI-supported cancer 0.296123 cancer cells 0.361641 Cancer Information Service 0.276024 patient 0.26688 lymph nodes 0.350794 treatment clinical trials 0.300384 National Cancer Institute 0.364736 swollen lymph nodes 0.277694 new treatment 0.302418 External radiation therapy 0.314938 neck 0.309398 cancer research process 0.269057 cancer clinical trials 0.358746 stage 0.310003 neck cancer 0.286172 lymph node 0.322344 cancer information summaries 0.27414 comprehensive cancer information 0.274558 cancer 0.901171 standard treatment 0.274055 Hypopharyngeal Cancer Treatment 0.314822	CLICK HERE
1664	National Cancer Institute	Html	en	Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood atypical teratoid/rhabdoid tumors	cancer treatment 0.542006 metastatic brain tumors 0.391418 ongoing clinical trials 0.389415 PDQ cancer information 0.511527 tumor suppressor genes 0.452709 clinical trial search 0.399694 brain tumors 0.444671 CNS atypical teratoid/rhabdoid 0.388691 clinical trials 0.847224 Pediatric Treatment Editorial 0.416481 Teratoid/Rhabdoid Tumor Treatment 0.445097 cancer information summary 0.463674 clinical trial 0.521041 cancer cells 0.510172 stem cell transplant 0.396934 patients 0.411179 primary brain tumors 0.3918 treatment clinical trial 0.409064 NCI PDQ cancer 0.42324 radiation therapy 0.555658 Treatment Editorial Board 0.420841 Cord Tumors Treatment 0.414346 late effects 0.393798 treatment 0.689522 new cancer treatments 0.395428	PDQ treatment summary 0.447943 childhood brain 0.385451 Cancer Information Service 0.399251 specific cancer cells 0.397642 PDQ Pediatric Treatment 0.40786 treatment clinical trials 0.444124 National Cancer Institute 0.458723 spinal cord 0.616147 tumor cells 0.437516 effects cancer treatment 0.421518 new treatment 0.427513 childhood cancer information 0.400212 External radiation therapy 0.395094 brain tumor 0.405279 brain 0.467984 atypical teratoid/rhabdoid tumor 0.982554 PDQ summary 0.439127 cancer clinical trials 0.434177 cancer information summaries 0.39809 comprehensive cancer information 0.397631 cancer 0.740574 appropriate cancer treatment 0.419383 standard treatment 0.391688 fast-growing tumor 0.388774	CLICK HERE
1840	National Cancer Institute	Html	es	Tratamiento de la enfermedad trofoblástica de la gestación (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la enfermedad trofoblástica de la gestación.	Obstet Gynecol 0.314049 calificación pronóstica 0.330592 Agarwal R 0.309981 gestational trophoblastic tumor 0.470216 gynecologic oncology 0.31949 gestational trophoblastic tumour 0.330225 Sin embargo 0.495025 largo plazo 0.308011 drug-resistant gestational trophoblastic 0.316646 trophoblastic tumor simulating 0.31025 gestational trophoblastic 0.969098 high-risk gestational trophoblastic 0.417868 site trophoblastic tumor 0.331006 Epithelioid trophoblastic tumor 0.331525 oncology group study 0.309029 retrospective observational study 0.310708 trophoblastic neoplasia with 0.311489 trophoblastic tumor 0.525373 newlands es 0.321142 gestational trophoblastic neoplasia 0.524164 Gynecol Oncol 0.321149 Database Syst Rev 0.308864 placental site trophoblastic 0.326491 chemorefractory gestational trophoblastic 0.316598 Reprod Med 0.395131	gynecologic oncology group 0.309183 Lancet Oncol 0.308542 Organización Mundial 0.310432 tumores trofoblásticos epitelioides 0.326002 Lurain JR 0.332449 metastatic gestational trophoblastic 0.30963 Holden L 0.308229 Cancer Staging Manual 0.311272 Féderation Internationale 0.320433 trophoblastic disease 0.450228 with gestational trophoblastic 0.311191 trophoblastic tumours 0.335737 Recurrent gestational trophoblastic 0.309132 Clin Oncol 0.324887 sistema nervioso central 0.319546 low-risk gestational trophoblastic 0.340233 Charing Cross 0.316962 Gynaecol Obstet 0.314146 persistent gestational trophoblastic 0.309878 Short D 0.308931 FIGO Committee 0.309443 Charing Cross Hospital 0.309844 Obstet Gynaecol 0.310271 AJCC Cancer Staging 0.31188	CLICK HERE
1883	National Cancer Institute	Html	es	Tratamiento de los tumores extracraneales de células germinativas en la niñez (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores extracraneales de células germinativas en la niñez.	cell tumor protocols 0.408279 germinativas malignas localización 0.405353 células germinativas seminomatosos.Seminoma 0.410393 cell tumor combined 0.407867 germ cell tumours 0.412186 Perlman EJ 0.405253 Calaminus G 0.412513 Cell Cancer Collaborative 0.406794 cell tumors from 0.406747 Göbel U 0.406021 Cancer Group 0.42074 cell tumor studies 0.407558 pediatric oncology 0.41388 células germinativas mixtos 0.417539 International Germ Cell 0.417008 Children's Oncology Group 0.409014 mediastinal germ 0.406328 cell tumor study 0.408368 <2 cm 0.405406 Metástasis peritoneales macroscópicas 0.405941 germ cell neoplasms 0.406391 Children's Cancer 0.42175 cell tumors show 0.406094 pediatric germ 0.426106 adultos jóvenes 0.40725	estadio iv 0.405826 ganglios linfáticos ≥2 0.411723 Germ Cell Consensus 0.412507 Cushing B 0.405386 teratomas benignos 0.407141 Genes Chromosomes Cancer 0.438953 with germ 0.406335 malignant germ cell 0.462527 PDQ Tratamiento 0.405882 childhood germ 0.409831 cell tumors based 0.405903 Clin Oncol 0.444548 saco vitelino 0.435575 linfáticos ≥2 cm 0.408554 Schneider DT 0.409517 Children's Cancer Group 0.419331 Cell Consensus Classification 0.409901 germ cell tumors 0.974328 Kingdom Children Cancer 0.408316 germ cell cancer 0.410294 Children's Cancer Study 0.409136 pediatric oncology group 0.410202 oncology group 0.420408 Cancer Study Group 0.411644	CLICK HERE
1973	National Cancer Institute	Html	es	Tratamiento del cáncer de glándulas salivales (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de glándulas salivales.	Neck Cancer 0.247421 siguientes procedimientos 0.717657 siguientes aspectos 0.315855 estadio ii 0.901856 vía oral 0.251714 rayos x 0.574567 pequeñas marcas 0.24571 enlace drugs approved 0.287895 exploración tac 0.270837 National Cancer Institute 0.238285 siguientes riesgos 0.235555 Instituto Nacional 0.352284 malla ayuda 0.248945	PDQ Tratamiento 0.283565 partículas minúsculas 0.2536 radioterapia envía neutrones 0.431263 presente sección 0.245937 explorador tep 0.281651 Physician Data Query 0.352077 estadio iii 0.736431 principales cánceres 0.411638 siguientes situaciones 0.301582 ganglio linfático mide 0.91402 cáncer.ampliar radioterapia 0.391316 siguientes enlaces 0.247009 siguientes pruebas 0.31121	CLICK HERE
2000	National Cancer Institute	Html	es	Tratamiento de la histiocitosis de células de Langerhans (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de la histiocitosis de células de Langerhans.	cuánto aire 0.415134 siguientes procedimientos 0.528715 células madre 0.858073 adultos jóvenes 0.464664 efectos secundarios meses 0.439126 siguientes aspectos 0.434701 faja ajustadora 0.428231 HCL infantil multisistémica 0.546722 cuántos sistemas 0.518567 genes ras 0.453948 pequeña cantidad 0.423844 células normales.ampliar exploración 0.532323 vía oral 0.42013 rayos x 0.425227 gen braf 0.666188 largo plazo 0.44968 cuántas células 0.518957 niño ayuda 0.426203 efectos tardíos 0.516221 escáner.ampliar exploración 0.429231 tarde.ampliar ecografía 0.427113	vías respiratorias 0.424871 causa problemas 0.424997 lesiones óseas 0.423193 National Cancer Institute 0.417904 IRMN).Ampliar Imágenes 0.421648 siguientes riesgos 0.415861 radiación uvb 0.414555 Instituto Nacional 0.431398 PDQ Tratamiento 0.451873 antecedentes familiares 0.589915 llamada genes ras 0.432872 explorador tep 0.430081 terapia fotodinámica causa 0.453098 sistema nervioso central 0.604707 Physician Data Query 0.464236 mayores probabilidades 0.416225 HCL multisistémica 0.966875 terapia fotodinámica llamada 0.451949 radiación ultravioleta 0.561342 siguientes pruebas 0.489919	CLICK HERE
3652	National Cancer Institute	Html	es	Cannabis y canabinoides (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del Cannabis y canabinoides para el tratamiento de los efectos secundarios relacionados con el tratamiento del cáncer, como la náusea y el vómito.	Natl Acad Sci 0.394203 cannabinoid receptor cb2 0.362796 Neck Cancer Epidemiology 0.340717 with peripheral cb1 0.353749 accessed october 0.451422 receptores cb2 0.414613 Sin embargo 0.375752 receptores cb1 0.617059 Mol Cancer Ther 0.460254 cb2 receptors 0.369543 marijuana as 0.341164 potencial receptor 0.334026 cannabinoid cb1 0.353877 Nat Rev Cancer 0.38837 receptor cb2 0.381409 receptor cb1 0.494644 endogenous cannabinoid 0.347836 Cancer Res 0.471447 Pharmacol Biochem Behav 0.366013 Marihuana Tax Act 0.373003 cannabinoid receptor activation 0.352792 lesiones premalignas 0.350108 cannabinoid receptor with 0.35689 Estados Unidos 0.902915 endogenous cannabinoid system 0.33287	Pain Symptom Manage 0.358772 endocannabinoid system as 0.404957 Integrating cannabis 0.433732 Pharmacol Rev 0.370877 Targeting CB2 cannabinoid 0.338858 ancient cannabis from 0.417929 Cannabidiol inhibits 0.365208 Proc Natl Acad 0.396634 canabinoides endógenos 0.435834 cannabinoid receptor 0.890303 CB2 receptor agonists 0.350942 cannabis sativa l 0.444025 Blázquez C 0.343327 chemokine receptor cxcr4 0.338077 Cannabis sativa extract 0.416057 cell proliferation 0.33314 sistema nervioso central 0.343143 breast cancer 0.515229 Cannabis medicinal 0.719247 receptores canabinoides 0.400314 emerging target 0.333482 Cannabis versus 0.409865 agonistas canabinoides 0.344588 CB2 cannabinoid 0.361915	CLICK HERE
15640	National Cancer Institute	Html	null	Research & Development (R&D) Contracts	null			CLICK HERE
16683	National Cancer Institute	Html	es	714-X (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del 714-X como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Alternative Medicine Confronts 0.349 Task Force 0.681834 Rock Forest 0.4465 Cancer Research Initiative 0.920081 Radiosensitizing effect 0.323708 but not 0.32369 Goel HC 0.323157 Alternative Therapeutic 0.727518 Bacteria Cause Cancer 0.362108 Unconventional therapies 0.71198 Breast Cancer Research 0.913503 saccharin-LiCl conditioned stimulus 0.34146 Roa AR 0.322774 transplantable mammary 0.323668 Instituto Nacional 0.49296 Pharmacol Biochem Behav 0.342417 Pavlovian conditioning 0.324132 PDQ 714-X 0.384196 posibles efectos 0.32412 Estados Unidos 0.547224 Canadian Breast Cancer 0.923206 for bacteria as 0.342644 vía nasal 0.324957 Purohit A 0.322533 New York University 0.333776	alcanfor mejora 0.352671 Conditioned enhancement 0.324112 linfoma caninos 0.323743 CERBE Distribution 0.468077 Solvason HB 0.367895 Hiramoto RN 0.325133 new approach 0.322794 empresa distribuidora 0.324674 National Cancer Institute 0.431242 Hiramoto NS 0.502986 vitamina b12 0.324597 New York 0.3535 accessed april 0.467486 Neurosci Res 0.325453 numerosos oligoelementos 0.325391 Physician Data Query 0.337084 Hess DJ 0.368799 libre uso 0.325033 linfosarcoma murinos 0.323938 Ghanta VK 0.432317 cartílago bovino 0.325426 killer cell activity 0.342736 response to yc8 0.339588 Soong SJ 0.323559	CLICK HERE